Phase 3 trial of 13-valent pneumococcal conjugate vaccine with concomitant trivalent influenza vaccine in adults aged 65 years or older

Phase 3, randomised, double-blind trial of pneumococcal 13-valent conjugate vaccine and trivalent inactivated influenza vaccine in pneumococcal disease and influenza (3 arms), sponsored by Wyeth. Primary endpoints: Immunologic noninferiority of concomitant trivalent influenza vaccine administration, Primary immunologic comparisons at 1 month and 1 more. Started Jul 2007; status: completed.